Previous experiments demonstrated that ANRIL could identify the risk of major harmful cardiovascular events in hemodialysis patients, which reveals that ANRIL participates in the progression of cardiovascular complications in CKD [27]. Here, CDKN2B-AS1 is linked to chronic kidney disease.